XML 70 R58.htm IDEA: XBRL DOCUMENT v3.25.2

Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (€)
€ / shares in Units, € in Millions

2 Months Ended

6 Months Ended

Jun. 30, 2025

Jun. 30, 2025

Jun. 30, 2024

^[1]

Dec. 31, 2024

Disclosure of transactions between related parties [line items]

Investments accounted for using the equity method

€ 3,563

€ 3,563

€ 316

Share of profit/(loss) from investments accounted for using the equity method

11

85

€ (22)

Associates and joint ventures

Disclosure of transactions between related parties [line items]

Amounts payable, related party transactions

637

€ 637

160

EUROAPI

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in associate

^[2]

29.60%

Investments in associates

^[2]

82

€ 82

82

Opella

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in associate

^[3]

48.20%

Investments in associates

^[3]

€ 3,239

€ 3,239

€ 0

Loans to Associates

^[3]

€ 241

EUROAPI

Disclosure of transactions between related parties [line items]

Stock price (in euro per share)

€ 2.89

€ 2.89

€ 0.0288

MSP Vaccine Company | MCM Vaccine BV

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in subsidiary

100.00%

Infraserv GmbH & Co. Höchst KG

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in joint venture

^[4]

31.20%

Investments in joint ventures

^[4]

€ 93

€ 93

€ 102

MSP Vaccine Company

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in joint venture

^[5]

50.00%

Investments in joint ventures

^[5]

79

€ 79

81

Other investments

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in joint venture

0.00%

Investments in joint ventures

€ 70

€ 70

€ 51

[1]	Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2]	The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (€2.89 as of June 30, 2025, and €2.88 as of December 31, 2024).
[3]	(a)Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a €241 million loan to OPAL JV Co being in substance part of the investment.
[4]	Joint venture.
[5]	Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV

X

- Definition

The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 24
-IssueDate 2024-01-01
-Paragraph 20
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 24
-IssueDate 2024-01-01
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_AmountsPayableRelatedPartyTransactions
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2024-01-01
-Paragraph 24
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph B16
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B16&doctype=Appendix&subtype=B
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 54
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_e&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of investments in joint ventures accounted for using the equity method. [Refer: Total for all joint ventures [member]; Investments accounted for using equity method]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Total for all joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInJointVenture
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 19B
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 85
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Loans to Associates

+ References

No definition available.

+ Details

Name:	sny_LoansToAssociates
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Stock Price

+ References

No definition available.

+ Details

Name:	sny_StockPrice
Namespace Prefix:	sny_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OpellaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=sny_EuroapiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=sny_MSPVaccineCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: